Core Insights - The case highlights the successful use of the SynCardia Total Artificial Heart to bridge a young patient with advanced biventricular heart failure to heart transplantation after 119 days of support [1][2][3] Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which produces the only commercially available total artificial heart technology approved by both the U.S. FDA and Health Canada [5] - The SynCardia Total Artificial Heart is the first artificial heart to receive regulatory approval in both the U.S. and Canada, and it is the most widely used artificial heart globally, with over 2,100 implants performed across 27 countries [5] Industry Context - The successful case at UCSF Health represents the second of five patients who have been bridged to transplantation using the SynCardia Total Artificial Heart, indicating the growing role of total artificial heart therapy in treating patients with severe heart failure [2][3] - The increasing adoption of the SynCardia Total Artificial Heart at leading transplant centers reflects the rising demand for advanced mechanical circulatory support for patients with end-stage heart failure [4]

Core Insights - A 29-year-old patient successfully received a donor heart transplant after being supported for over 1,600 days by the SynCardia Total Artificial Heart, demonstrating the device's effectiveness as a bridge to transplant [1][2]. Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which produces the SynCardia Total Artificial Heart, the first total artificial heart approved by both the U.S. FDA and Health Canada [5]. - The SynCardia Total Artificial Heart is the only commercially available artificial heart in the U.S. and Canada, with over 2,100 implants performed across 27 countries [5]. Product Functionality - The SynCardia Total Artificial Heart replaces the pumping function of both sides of the heart, maintaining circulation for patients with irreversible biventricular heart failure while they await a donor organ [2][3]. - The device restores circulation and hemodynamic stability by replacing both ventricles and all four native heart valves [3]. Clinical Impact - More than 2,100 implants of the SynCardia Total Artificial Heart have been performed worldwide, with the longest documented support exceeding eight years [4]. - Extended duration support cases continue to inform clinical practice and illustrate the potential for long-term mechanical circulatory support in carefully selected patients [4].

Core Insights - Picard Medical, Inc. is advancing its leadership in artificial heart technology with the SynCardia Total Artificial Heart and the next-generation Emperor system, focusing on not just survival but also quality of life and transplant eligibility [1][2]. Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is the only provider of commercially available total artificial heart technology for end-stage heart failure patients [5]. - The SynCardia Total Artificial Heart (STAH) is the first artificial heart approved by both the U.S. FDA and Health Canada, with over 2,100 implants performed globally [5]. Conference Participation - Dr. Andre Simon, Vice President of Clinical Affairs, will present at the Technology and Heart Failure Therapeutics (THT) 2026 conference, showcasing the company's commitment to innovation and education in heart failure therapies [1][2]. - The conference will feature discussions on emerging technologies and clinical data aimed at improving patient outcomes in heart failure management [4]. Presentation Highlights - Dr. Simon's presentations will cover: - The Emperor system's early laboratory and preclinical data, emphasizing its design for improved patient mobility and independence [2]. - Future priorities in total artificial heart therapy, including earlier intervention and organ recovery [3]. - Updated registry analyses demonstrating that outcomes with the STAH extend beyond survival to include functional improvement and quality of life enhancements [3].